Current treatment for cutaneous lupus erythematosus (CLE) commonly focuses on photoprotection, topical therapies, corticosteroids, antimalarial drugs, and immunosuppressive drugs. More recently, B-cell depleting therapies, such as rituximab, have shown promise in treating systemic lupus erythematosus, though the feasibility of treating CLE with rituximab has not been well described.
Current treatment for cutaneous lupus erythematosus (CLE) commonly focuses on photoprotection, topical therapies, corticosteroids, antimalarial drugs, and immunosuppressive drugs. More recently, B-cell depleting therapies, such as rituximab, have shown promise in treating systemic lupus erythematosus (SLE), though the feasibility of treating CLE with rituximab has not been well described. Now, a paper newly published in JAMA Dermatology reports on one of the largest cohorts of rituximab-treated patients with SLE and response according to CLE subtype.
The retrospective observational study included 709 patients with SLE who were treated at the University College London Hospital in the United Kingdom between 2000 and 2016. Patients were enrolled through the center’s database.
In total, 150 of these patients were treated with rituximab; 57 patients in this treatment group had mucocutaneous British Isles Lupus Assessment Group (BILAG) grades of A or B, and 50 were included in the analysis. With respect to CLE subtypes, acute CLE (ACLE) was most prevalent (46%), while 6 patients had subacute CLE (SCLE) features (12%), 10 had chronic CLE (CCLE) (24%), and 11 had nonspecific SLE (NSLE) (22%).
Ten of the patients had previous rituximab treatment, and 40 were rituximab naïve. In total, 46 patients received 2 infusions of 1 g of rituximab, and 4 patients received a single infusion due to adverse events or logistical considerations.
At 6 months after treatment, 38 patients (76%) demonstrated a clinical response, and 20 (40%) demonstrated a complete response. Those with the NSLE subtype had the highest proportion (45%) of patients with a BILAG grade reduction to D. Of the remaining patients, 18 (36%) had a partial response and 8 (16%) had stable disease.
At 12 months after infusion, 28 (61%) of the 46 patients with follow-up available demonstrated clinical response, 24 (52%) demonstrated complete response, and the ACLE and SSLE subtypes had similarly high response rates of 57% and 60%, respectively.
At 6 months, 5 (88%) of the patients with SCLE and 10 (83%) of the patients with CCLE demonstrated a clinical response, including complete response in 2 (33%) patients in the SCLE group and 5 (42%) of patients in the CCLE group.
At 12 months, 3 (50%) of patients with SCLE and 7 (64%) of patients with CCLE demonstrated clinical response, including complete response in 2 (33%) and 5 (45%) patients in the 2 groups, respectively.
Of the 50 patients who received rituximab, 32 (64%) required an additional treatment cycle either during or after the follow-up period, however.
While the study was limited by its retrospective nature and the small number of patients within each CLE subtype, the authors concluded that their results show good clinical response to B-cell depletion with rituximab in all forms of mucocutaneous involvement with SLE, especially in patients with ACLE and NSLE. While patients with CCLE responded well, their small numbers warrant further study.
Reference
Quelhas da Costa R, Aguirre-Alastuey E, Isenberg DA, Saracino AM. Assessment of response to B-cell depletion using rituximab in cutaneous lupus erythematosus [published online October 31, 2018]. JAMA Dermatol. doi:10.1001/jamadermatol.2018.3793.
Julie Reed: Why 2024 Is Important for Biosimilars
April 17th 2024Julie Reed, executive director of the Biosimilars Forum, showcases how the biosimilar industry is expected to develop throughout 2024, including major policy changes and hope for continued improvement in market share for adalimumab biosimilars.
Decoding the Patent Puzzle: Navigating the Legal Landscape of Biosimilars
March 17th 2024On this episode of Not So Different, Ha Kung Wong, JD, an intellectual patent attorney and partner at Venable LLP, details the confusing landscape that is the US patent system and how it can be improved to help companies overcome barriers to biosimilar competition.
Alvotech’s Stelara Biosimilar, Selarsdi, Receives FDA Approval
April 16th 2024Alvotech’s Selarsdi (ustekinumab-aekn), a biosimilar referencing Stelara (ustekinumab), gained FDA approval, making it the second ustekinumab biosimilar and second for the company to be given the green light for the American market.
Biosimilars Rheumatology Roundup for February 2024—Podcast Edition
March 3rd 2024On this episode of Not So Different, The Center for Biosimilars® revisited all the major rheumatology biosimilar news from February 2024, including the FDA approval of the 10th adalimumab biosimilar, the promise for an oral delivery system for ustekinumab, and the impact of adalimumab products on COVID-19 antibodies.
Global Biosimilar Market Projected to Reach $1.3 Trillion by 2032
April 11th 2024The global biosimilar market is projected to surge from $25.1 billion in 2022 to approximately $1.3 trillion by 2032, with a compound annual growth rate of 17.6%, driven mainly by the increasing prevalence of cancer and the cost-effectiveness of biosimilars, as outlined in a report by Towards Healthcare.
Biosimilars Council: PBM Rebate Schemes Cost Americans, Payers $6 Billion
April 10th 2024A report from the Biosimilars Council evaluating IQVIA data found that rebate schemes orchestrated by pharmacy benefit managers (PBMs) are costing US patients and payers billions of dollars by suppressing biosimilar adoption.